Business Context and Reporting Period
This Form 8-K is a current report filed by AlloVir, Inc. (not Kalaris Therapeutics, Inc.) on June 21, 2023. The registrant is a Delaware corporation with its principal executive offices in Waltham, Massachusetts, and its common stock trades on the Nasdaq Global Select Market under the symbol ALVR. The company is classified as an emerging growth company.
Key Financial Metrics
This filing is a current report regarding a corporate event and does not contain financial statements. Consequently, there are no reported values for revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes
The material event reported is the suspension and termination of the ATM Prospectus Supplement associated with the Sales Agreement dated August 6, 2021, between AlloVir and SVB Securities LLC. As a result:
- AlloVir has suspended its use of the prospectus supplement.
- The company will not make any sales of its securities pursuant to the Sales Agreement unless and until a new prospectus supplement or a new registration statement is filed.
- Other than the termination of the prospectus supplement, the underlying Sales Agreement remains in full force and effect.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. The primary risk disclosed is the immediate inability to raise capital through the existing At-The-Market (ATM) offering mechanism until a new registration is completed. No other contingencies or unusual items are described in this report.
Investor Verification Checklist
- Verify the status of the Sales Agreement with SVB Securities LLC to confirm if a new prospectus supplement has been filed.
- Review recent 10-Q or 10-K filings to assess the company's current cash position and runway given the suspension of the ATM facility.
- Confirm the company's classification as an emerging growth company and any implications for financial reporting standards.